132 related articles for article (PubMed ID: 2557881)
1. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.
Lai CL; Wu PC; Lok AS; Lin HJ; Ngan H; Lau JY; Chung HT; Ng MM; Yeoh EK; Arnold M
Br J Cancer; 1989 Dec; 60(6):928-33. PubMed ID: 2557881
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.
Lai CL; Wu PC; Chan GC; Lok AS; Lin HJ
Cancer; 1988 Aug; 62(3):479-83. PubMed ID: 2839280
[TBL] [Abstract][Full Text] [Related]
3. Serum hepatitis B viral DNA in HBsAg-positive hepatocellular carcinoma treated with interferon or adriamycin.
Lin HJ; Lai CL; Wu PC
Br J Cancer; 1986 Jul; 54(1):67-73. PubMed ID: 3015183
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Yeo W; Mok TS; Zee B; Leung TW; Lai PB; Lau WY; Koh J; Mo FK; Yu SC; Chan AT; Hui P; Ma B; Lam KC; Ho WM; Wong HT; Tang A; Johnson PJ
J Natl Cancer Inst; 2005 Oct; 97(20):1532-8. PubMed ID: 16234567
[TBL] [Abstract][Full Text] [Related]
5. Recombinant leukocyte A interferon with doxorubicin. A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma.
Creagan ET; Long HJ; Frytak S; Moertel CG
Cancer; 1988 Jan; 61(1):19-22. PubMed ID: 2825959
[TBL] [Abstract][Full Text] [Related]
6. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma.
Feun LG; Savaraj N; Hung S; Reddy R; Jeffers L; Benedetto P; Livingstone AS; Ardalan B; Levi JU; Parker T
Am J Clin Oncol; 1994 Oct; 17(5):393-5. PubMed ID: 8092109
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.
Lai CL; Lau JY; Wu PC; Ngan H; Chung HT; Mitchell SJ; Corbett TJ; Chow AW; Lin HJ
Hepatology; 1993 Mar; 17(3):389-94. PubMed ID: 8383088
[TBL] [Abstract][Full Text] [Related]
9. Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC).
Kountouras J; Boura P; Karolides A; Zaharioudaki E; Tsapas G
Hepatogastroenterology; 1995 Feb; 42(1):31-6. PubMed ID: 7782031
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease.
Creagan ET; Frytak S; Long HJ; Kvols LK
Cancer; 1989 Sep; 64(5):1034-7. PubMed ID: 2474365
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma.
Söderdahl G; Bäckman L; Isoniemi H; Cahlin C; Höckerstedt K; Broomé U; Mäkisalo H; Friman S; Ericzon BG
Transpl Int; 2006 Apr; 19(4):288-94. PubMed ID: 16573544
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).
Eggermont AM; Weimar W; Tank B; Dekkers-Bijma AM; Marquet RL; Lameris JS; Westbroek DL; Jeekel J
Cancer Immunol Immunother; 1986; 21(1):81-4. PubMed ID: 3632919
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interferon alfa given before and in combination with standard chemotherapy in children with acute lymphoblastic leukemia in first marrow relapse: a Pediatric Oncology Group pilot study.
Ochs J; Brecher ML; Mahoney D; Vega R; Pollock BH; Buchanan GR; Whitehead VM; Ravindranath Y; Freeman AI
J Clin Oncol; 1991 May; 9(5):777-82. PubMed ID: 2016619
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication.
Olweny CL; Toya T; Katongole-Mbidde E; Mugerwa J; Kyalwazi SK; Cohen H
Cancer; 1975 Oct; 36(4):1250-7. PubMed ID: 169983
[TBL] [Abstract][Full Text] [Related]
17. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
18. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
19. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.
Falkson G; MacIntyre JM; Schutt AJ; Coetzer B; Johnson LA; Simson IW; Douglass HO
J Clin Oncol; 1984 Jun; 2(6):581-4. PubMed ID: 6327926
[TBL] [Abstract][Full Text] [Related]
20. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial.
Feun LG; O'Brien C; Molina E; Rodriguez M; Jeffers L; Schiff ER; Marini A; Savaraj N; Ardalan B
J Cancer Res Clin Oncol; 2003 Jan; 129(1):17-20. PubMed ID: 12618896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
